US FDA issues 8 observations to Aurobindo Pharma's mfg unit in Telangana
This story was originally published at 20:06 IST on 5 September 2025
Register to read our real-time news.Informist, Friday, Sept. 5, 2025
--US FDA issues 8 observations to Aurobindo Pharma's unit in Telangana
MUMBAI – Aurobindo Pharma Ltd. Friday said the US Food and Drug Administration has issued eight observations to the company's oral solid and injectable manufacturing unit at Bachupally in Telangana. The drug regulator has inspected the unit from Aug. 25 to Friday, the pharmaceutical company said in an exchange filing. "We will respond to the US FDA within the stipulated timelines," it said.
For the quarter ended June, the company had reported a consolidated net profit of INR 8.25 billion on revenue of INR 78.68 billion. Its shares closed at INR 1,044.10 Friday on the National Stock Exchange, up 0.8%. End
Reported by Anjana Therese Antony
Edited by Akul Nishant Akhoury
For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.
Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.
Informist Media Tel +91 (22) 6985-4000
Send comments to feedback@informistmedia.com
© Informist Media Pvt. Ltd. 2025. All rights reserved.
To read more please subscribe
Share this Story:
